Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

Jeffrey A Allen; Jie Lin; Tina Dysgaard; Christian Eggers; Jeffrey T Guptill; Kelly G Gwathmey; Channa Hewamadduma; Erik Hofman; Yessar M Hussain; et al.

doi:10.1016/S1474-4422(24)00309-0

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

Jeffrey A Allen
, Jie Lin
, Tina Dysgaard
, Christian Eggers
, Jeffrey T Guptill
, Kelly G Gwathmey
, Channa Hewamadduma
, Erik Hofman
, Yessar M Hussain
, et al.

Department of Neurology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1013-1024
Number of pages	12
Journal	The Lancet Neurology
Volume	23
Issue number	10
DOIs	https://doi.org/10.1016/S1474-4422(24)00309-0
Publication status	Published - Oct 2024

Fields of science

302052 Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1474-4422(24)00309-0

Cite this

A Allen, J., Lin, J., Dysgaard, T., Eggers, C., T Guptill, J., Gwathmey, K. G., Hewamadduma, C., Hofman, E., Hussain, Y. M., & et al. (2024). Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 23(10), 1013-1024. https://doi.org/10.1016/S1474-4422(24)00309-0

@article{5b6adcb50c634c458ec3db8c3082a00e,

title = "Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial",

author = "\{A Allen\}, Jeffrey and Jie Lin and Tina Dysgaard and Christian Eggers and \{T Guptill\}, Jeffrey and Gwathmey, \{Kelly G\} and Channa Hewamadduma and Erik Hofman and Hussain, \{Yessar M\} and \{et al.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = oct,

doi = "10.1016/S1474-4422(24)00309-0",

language = "English",

volume = "23",

pages = "1013--1024",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "ELSEVIER SCIENCE INC",

number = "10",

}

A Allen, J, Lin, J, Dysgaard, T, Eggers, C, T Guptill, J, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM & et al. 2024, 'Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial', The Lancet Neurology, vol. 23, no. 10, pp. 1013-1024. https://doi.org/10.1016/S1474-4422(24)00309-0

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. / A Allen, Jeffrey; Lin, Jie; Dysgaard, Tina et al.
In: The Lancet Neurology, Vol. 23, No. 10, 10.2024, p. 1013-1024.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

AU - A Allen, Jeffrey

AU - Lin, Jie

AU - Dysgaard, Tina

AU - Eggers, Christian

AU - T Guptill, Jeffrey

AU - Gwathmey, Kelly G

AU - Hewamadduma, Channa

AU - Hofman, Erik

AU - Hussain, Yessar M

AU - et al., null

PY - 2024/10

Y1 - 2024/10

UR - https://www.scopus.com/pages/publications/85203972760

U2 - 10.1016/S1474-4422(24)00309-0

DO - 10.1016/S1474-4422(24)00309-0

M3 - Article

SN - 1474-4422

VL - 23

SP - 1013

EP - 1024

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 10

ER -

A Allen J, Lin J, Dysgaard T, Eggers C, T Guptill J, Gwathmey KG et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

Fields of science

UN SDGs

Access to Document

Other files and links

Cite this